# OnCo record raloxifene (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/raloxifene/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "raloxifene" ;
  schema:name "Raloxifene"@en ;
  schema:description "Raloxifene (Evista) is an osteoporosis tablet that also lowers the chance of developing invasive breast cancer in postmenopausal women at higher risk, with fewer womb-cancer problems than tamoxifen."@en ;
  schema:url <https://onco.cc/drugs/raloxifene/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Raloxifene> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=raloxifene>, <https://www.cancer.gov/about-cancer/treatment/drugs/raloxifenehydrochloride> ;
  onco:status "approved" ;
  onco:tag "nci-list", "prevention" ;
  onco:modality "Selective oestrogen receptor modulator (benzothiophene)" ;
  schema:alternateName "Evista" ;
  onco:approval "US 1997: Treatment and prevention of postmenopausal osteoporosis", "US 2007: Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk" ;
  onco:related <https://onco.cc/drugs/tamoxifen/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:trials <https://onco.cc/trials/nct06062810/> .